Comparative Pharmacology
Head-to-head clinical analysis: CLOBETASOL PROPIONATE versus CORTALONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOBETASOL PROPIONATE versus CORTALONE.
CLOBETASOL PROPIONATE vs CORTALONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and suppression of immune response via modulation of gene expression.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response, and regulate metabolism.
Apply topically as a thin film to affected areas once to twice daily. Maximum 50 g/week. Treatment duration not to exceed 2 consecutive weeks.
10-40 mg orally once daily in the morning; for acute exacerbations, up to 60 mg/day divided into 2-4 doses.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours after topical application. However, due to prolonged cutaneous retention, clinical effects may persist beyond systemic elimination.
Clinical Note
moderateClobetasol propionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gatifloxacin."
Clinical Note
moderateClobetasol propionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rosoxacin."
Clinical Note
moderateClobetasol propionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal (biliary) with minimal renal excretion. Less than 5% of a topical dose is recovered in urine as metabolites; the majority is eliminated via feces after hepatic metabolism.
Primarily renal (60-70% as unchanged drug), with 10-20% biliary/fecal.
Category A/B
Category C
Topical Corticosteroid
Topical Corticosteroid
Clobetasol propionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Trovafloxacin."